FDA Approves First Targeted Therapy for CSU in More Than a Decade
The Dermatology Digest
APRIL 18, 2025
The post FDA Approves First Targeted Therapy for CSU in More Than a Decade appeared first on The Dermatology Digest.
Dermatology Safety Therapy 
Red Light Therapy Masks: Best Anti-Ageing Treatment for Firmer Skin After 40
Alison Bladh
APRIL 28, 2025
One treatment that has captured a lot of attention recently is red light therapy and it is easy to see why. In this blog, Ill explain what red light therapy is in simple terms, why it can be especially powerful for women over 40, and what to look for when choosing a red light therapy mask for your skincare routine.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Icotrokinra Shows Efficacy and Safety in Adolescents With Moderate to Severe PsO
The Dermatology Digest
APRIL 10, 2025
These data were presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting in Buenos Aires, Argentina. ” Icotrokinra demonstrated a favorable safety profile. In the study, 84.1% achieved a Psoriasis Area and Severity Index (PASI) 90 response, compared to 27.3% and Janssen Biotech, Inc.,
Safety 
36
36 
The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies
Dermatology Times
APRIL 25, 2025
Alexandra Golant, MD, discusses how advancements in pediatric atopic dermatitis (AD) treatment, including topical Janus kinase (JAK) inhibitors like ruxolitinib, may reshape guidelines, yet hurdles remain in regulatory approval, safety data, and accessibility. Adoption depends on efficacy, cost, insurance, and caregiver education.
Dermatitis 36
36 
U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN
The Dermatology Digest
FEBRUARY 18, 2025
It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. Every treatment approval is hard-won, built on research, persistence, and partnership.
Networking 64
64 
TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology
The Dermatology Digest
JULY 24, 2024
Stelara is a currently approved treatment for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s, and moderately to severely active ulcerative colitis.
Dermatology 78
78 
Fostering Patient Wellness: Prioritizing Safety and Education in PDE4 Utilization
Dermatology Times
JANUARY 9, 2024
Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.
Safety 77
77 
AnaptysBio Drops AD Drug After Phase 2 Trial Misses Its Marks
The Dermatology Digest
DECEMBER 11, 2024
Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.
Safety 36
36 
Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO
The Dermatology Digest
MARCH 10, 2025
improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.
Welcome to the “Golden age” of PN: Ruxolitinib Cream 1.5% (Opzelura, Incyte) Shows Early Improvement in Itch and Skin Lesions
The Dermatology Digest
MARCH 8, 2025
The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% The overall safety profile of ruxolitinib cream 1.5%
Safety 36
36 
Using CO2 Laser + Other Modalities to Treat Skin Pigmentation
Lipgloss and Aftershave
NOVEMBER 1, 2024
Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. Journal of Dermatological Science. Journal of the American Academy of Dermatology. Dermatologic Therapy.
U.S. FDA Grants Orphan Drug Designation for Restem’s ULSC Program for the Treatment of Dermatomyositis and Polymyositis
The Dermatology Digest
DECEMBER 4, 2024
Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals.
Treatments 36
36 
Palvella Therapeutics’ QTORIN Rapamycin 3.9% Anhydrous Gel Shows Promise for Microcystic LMs
The Dermatology Digest
APRIL 11, 2025
anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. Food and Drug Administration (FDA)-approved therapies for microcystic LMs. Palvella Therapeutics, Inc. There are no U.S.
Therapy 36
36 
U.S. FDA Approves IND for Ruxoprubart in DM
The Dermatology Digest
FEBRUARY 25, 2025
This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported. FDA Approves IND for Ruxoprubart in DM appeared first on The Dermatology Digest. The post U.S.
Safety 36
36 
A Glimpse Inside the Lichen Planus Pipeline
The Dermatology Digest
NOVEMBER 30, 2024
Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.
EMA’s CHMP Recommends Krystal’s Vyjuvek for Dystrophic Epidermolysis Bullosa
The Dermatology Digest
MARCH 3, 2025
We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives, says Cristina Has, MD, Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany, in a news release.
Therapy 36
36 
Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 HS Studies
The Dermatology Digest
MARCH 17, 2025
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%
Safety 36
36 
FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar
The Dermatology Digest
JULY 1, 2024
PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.
Portfolios 74
74 
Journal Digest: June 4
Dermatology Times
JUNE 4, 2024
This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.
Safety 69
69 
Godfrey Town has been appointed Senior Research Fellow
Online Laser Training
OCTOBER 11, 2019
Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.
Hospital 78
78 
Godfrey Town has been appointed Senior Research Fellow
Online Laser Training
OCTOBER 11, 2019
Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.
Hospital 78
78 
GPP Therapies: Comparing Efficacy and Safety of Secukinumab and Ustekinumab
Dermatology Times
OCTOBER 4, 2024
While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.
Therapy 45
45 
AD Pipeline Watch: First Patient Enrolled in Phase 2 Study of Evommune’s IL-18 Blocker
The Dermatology Digest
MARCH 17, 2025
The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis.
Dermatitis 36
36 
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Dermatology Times
MARCH 28, 2025
Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.
Safety 36
36 
Don’t Miss Out: La Roche-Posay Calls for 2024 Young Investigator Grant Applicants, Announces 2023 Grant Winners
The Dermatology Digest
OCTOBER 30, 2024
Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.
New Ladder Helps Guide Choice of Non-steroidal Treatments in AD
The Dermatology Digest
APRIL 7, 2024
The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.
Treatments 77
77 
A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments
Dermatology Times
JULY 4, 2024
The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.
Safety 36
36 
Otezla Now Available for Kids With Moderate to Severe Psoriasis
The Dermatology Digest
AUGUST 20, 2024
Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.
Safety 74
74 
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Dermatology Times
APRIL 4, 2025
Aaron Farberg, MD, discuss how to educate parents about the potential adverse effects of a new therapy while also reassuring them about its overall safety profile by providing clear, evidence-based information and emphasizing the rigorous testing and monitoring processes.
Safety 36
36 
Meet the First-ever Recipients of The Lupus Research Alliance’s Translational Bridge Award
The Dermatology Digest
NOVEMBER 6, 2024
This could help doctors better predict which therapies will work best for each patient. He will test ONT01, which has shown promising results in mouse models, in a phase 1b trial to assess its safety in people with lupus. This trial could open the door to a new class of treatments that target lupus at the molecular level.
Hospital 36
36 
INmune Bio to Submit FDA BLA for CORDStrom in RDEB
The Dermatology Digest
FEBRUARY 10, 2025
The submission will be supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. The post INmune Bio to Submit FDA BLA for CORDStrom in RDEB appeared first on The Dermatology Digest.
Hospital 36
36 
Exploring Oral Options for Psoriasis Therapies
US Dermatologt Partners
JUNE 1, 2024
In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. 1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals. 7 Oral Options vs.
Therapy 41
41 
Maui Derm News: Delgocitinib Cream Bests Alitretinoin in Phase 3 CHE Trial
The Dermatology Digest
JANUARY 29, 2025
The topical pan-Janus kinase (JAK) inhibitor demonstrated superior treatment effects, quality of life improvements, and a more favorable safety profile compared to oral alitretinoin over 24 weeks. A systemic therapy, alitretinoin, is approved in Canada, the European Union, South Korea, and Israel.
Eczema 36
36 
Radio Frequency Technology: Skin Laxity and Body Contouring
Lipgloss and Aftershave
APRIL 21, 2025
Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. Uses real-time temperature feedback for safety. LED Therapy: Reduces inflammation + speeds recovery.
Technology 52
52 
VYN201 for Vitiligo: Phase 1b Study Confirms Safety
Dermatology Times
NOVEMBER 1, 2024
VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.
Safety 57
57 
Acne Extractions: How to Get Rid of Pimples Safely with a Dermatologist
US Dermatologt Partners
JANUARY 13, 2025
Dermatology Partners Fairfax , Whether patients are dealing with persistent blackheads, painful cystic acne, or stubborn whiteheads, the temptation to pop or pick at acne is hard to resist. Schedule a Dermatologic Consultation Ready to say goodbye to acne breakouts? According to Dr. Kavya Desai of U.S. What Are Acne Extractions?
Extractions 41
41 
Galderma’s Nemolizumab Approved for AD and PN in the UK and Switzerland
The Dermatology Digest
FEBRUARY 18, 2025
I am looking forward to offering my patients this new treatment option which has the potential to address their most troublesome symptoms, says Curdin Conrad, MD, a Professor of Dermatology and Head of Policlinic and the center for psoriasis at Lausanne University Hospital in Switzerland, in a news release.
Dermatitis 36
36 
“Comforting and Encouraging” Study Shows JAK Inhibitors Not Linked to Short-Term Heart Woes in Derm Patients
The Dermatology Digest
FEBRUARY 11, 2024
By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509
Dermatology 74
74 
AD Pipeline Watch: U.S. FDA Fast Tracks Nektar Therapeutics’ AD Candidate
The Dermatology Digest
FEBRUARY 10, 2025
Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. FDA Fast Tracks Nektar Therapeutics AD Candidate appeared first on The Dermatology Digest. ” The post AD Pipeline Watch: U.S.
Dermatitis 36
36 
Crafting Your Career: Medical Aesthetics
New Age Spa Institute
DECEMBER 18, 2024
Also known as NASI , this private beauty school in Des Plaines, IL offers training programs for professional licensing in esthetics, massage therapy, makeup, and more. Certifications are targeted programs designed to enhance your knowledge and skills in specific areas of esthetics, cosmetology, or massage therapy.
Medical 52
52 
Patient Enrollment Complete in Phase 3 Study of aminolevulinic acid HCI 10% (Ameluz, Biofrontera) for the Treatment of AK on the Extremities, Neck, and Trunk
The Dermatology Digest
MARCH 18, 2025
has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. Biofrontera Inc.
Treatments 36
36 
More Breaking News: U.S. FDA Approves Nemolizumab (Nemluvio, Galderma) for Patients with Moderate to Severe AD
The Dermatology Digest
DECEMBER 13, 2024
Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.
Dermatitis 69
69 
Milestone Alert: First Subject Dosed in Phase 2b Vitiligo Trial of Novel BET Inhibitor
The Dermatology Digest
JUNE 5, 2024
The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo.
Safety 73
73 
Managing Pemphigoid Gestationis in Pregnancy: Clinical Insights and Treatment Recommendations
Dermatology Times
JANUARY 8, 2024
Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.
Clinic 78
78 
Let's personalize your content